Myeloma2018 Session III

 

Epigenetics

Session III of Myeloma2018 featured experts Felipe Prosper, PhD, Brian Walker, PhD, and Constantine Mitsiades, MD, PhD, presenting on the role of epigenetics in multiple myeloma (MM) disease progression.
Several topics were discussed, including chromatin abnormalities, translocations, super-enhancers, mechanisms of resistance, and their association with transcriptional deregulation in MM.

Presentations
Myeloma and B-cell Differentiation Epigenetics
Felipe Prosper, PhD
University of Navarra Clinic, Navarra, Spain
8 September, 2018

Felipe Prosper, PhD, from the University of Navarra Clinic, Navarra, Spain, discusses epigenetics underlying myeloma and disease progression.

Epigenetic Basis of Structural Changes
Brian Walker, PhD
UAMS Myeloma Institute, Little Rock, AR
8 September, 2018

Brian Walker, PhD, from the UAMS Myeloma Institute, Little Rock, AR, speaks about the epigenetic basis of structural changes in multiple myeloma.

Defining Mechanisms of Resistance and Novel Therapeutic Targets Through CRISPR-based Studies
Constantine Mitsiades, MD, PhD
Dana-Farber Cancer Institute, Boston, MA
8 September, 2018

Constantine Mitsiades, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses the defining mechanisms of resistance and novel therapeutic targets through CRISPR-based studies.